Marimed (MRMD) Common Equity (2011 - 2026)

Marimed (MRMD) has reported Common Equity for 16 consecutive years, with $43.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 24.05% year-over-year to $43.2 million in Q2 2026; TTM through Jun 2026 was $43.2 million, a 24.05% decrease from a year earlier, with the FY2025 full-year figure at $50.0 million, down 14.58% from the prior year.
• Common Equity was $43.2 million for Q2 2026 at Marimed, down from $46.5 million in the prior quarter.
• Over five years, Common Equity peaked at $80.9 million in Q2 2023 and troughed at $43.2 million in Q2 2026.
• A 5-year average of $60.2 million and a median of $58.2 million in 2024 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 196.47% in 2022, down 90.0% in 2022.
• Over 5 years, Common Equity stood at $57.3 million in 2022, then climbed by 20.2% to $68.9 million in 2023, then declined by 15.01% to $58.5 million in 2024, then slipped by 14.58% to $50.0 million in 2025, then dropped by 13.53% to $43.2 million in 2026.
• The last three Common Equity figures came in at $43.2 million (Q2 2026), $46.5 million (Q1 2026), and $50.0 million (Q4 2025), per Business Quant data.